The FINANCIAL — Johnson & Johnson on October 5 announced the completion of the divestiture of its Cordis business to Cardinal Health for an approximate value of $2 billion, subject to customary adjustments.
The Cordis business is one of the global leaders in the development and manufacture of interventional vascular technology and generated net revenues of approximately $780 million in 2014, according to Johnson & Johnson.
Johnson & Johnson remains dedicated to combating cardiovascular disease through its electrophysiology business, Biosense Webster, in the Medical Devices segment, and its leading cardiovascular medicine, XARELTO, in the Pharmaceutical segment.
Discussion about this post